ArticleLife (Basel, Switzerland)2021
Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters' Levels, but Has No Effect on Body Composition Parameters.
Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Phenotype-dependent effects of IL-17A inhibitors on lipid profiles in moderate-to-severe plaque psoriasis: a retrospective cohort study.Lipids in health and disease · 2026Article
- [Influence of long-term biologic therapy on metabolic biochemical parameters in moderate to severe plaque psoriasis].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Article
- Biologic Therapy and Cardiometabolic Risk in Psoriasis: A Retrospective Review.Dermatology and therapy · 2025Article
- Association of METS-IR index with psoriasis in US adults: a cross-sectional study.Scientific reports · 2024Article
- Residual metabolic burden in young psoriasis patients successfully treated with biologics.Archives of dermatological research · 2024Article
- Association between lipid accumulation product and psoriasis among adults: a nationally representative cross-sectional study.Lipids in health and disease · 2024Article
- An Overview of Growth Factors as the Potential Link between Psoriasis and Metabolic Syndrome.Journal of clinical medicine · 2023Review
- Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.International journal of molecular sciences · 2023Review
- Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes.Frontiers in microbiology · 2023Article
- Can Biological Drugs Diminish the Risk of Sarcopenia in Psoriatic Patients? A Systematic Review.Life (Basel, Switzerland) · 2022Review
- An Analysis ofJournal of clinical medicine · 2021Article
- Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasis is frequently accompanied by metabolic syndrome. Effect of anti-tumor necrosis factor therapies on increases in body weight is well-known. Data on the effects of interleukin-17 inhibitors are limited. Authors determined the effect of anti-interleukin-17 therapies on the body composition and serum lipid and inflammatory parameters among severe psoriatic patients.
methodsThirty-five severe psoriatic patients were enrolled. Twenty-two received secukinumab and 13 received ixekizumab as their 2nd-or 3rd-line biological treatment. Before treatment initiation and 6 months later, laboratory examinations measuring metabolic and inflammatory panels and body composition analyses were performed.
resultsAfter 6 months, a significant reduction was observed in psoriasis area severity index (
conclusionsAnti-interleukin-17 therapy of severe psoriatic patients does not cause significant changes in body composition parameters. Improvements in the lipid and inflammatory parameters might have a beneficial effect on patients' cardiometabolic status. This effect might be detectable in high-risk obese psoriatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.